Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 31Carcinoma, Renal Cell 19Carcinoma, Non-Small-Cell Lung 19Neoplasm Metastasis 11Carcinoma, Hepatocellular 9Brain Neoplasms 8Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Neoplasms 5Lung Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Transitional Cell 5Uveal Melanoma 4Skin Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Mesothelioma 4Kidney Neoplasms 4Glioblastoma 4Carcinoma, Basal Cell 4Carcinoma 4Sarcoma 3Recurrence 3Myelodysplastic Syndromes 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Gliosarcoma 3Colorectal Neoplasms 3Breast Neoplasms 3

Interventions

durvalumab 8Bevacizumab 7tremelimumab 4lenvatinib 3atezolizumab 3Nivolumab 3Ipilimumab 3fludarabine 2Magnetic Resonance Imaging 2Hepatectomy 2Gemcitabine 2Cyclophosphamide 2Cisplatin 2trastuzumab deruxtecan 1toripalimab 1ropidoxuridine 1poly ICLC 1pembrolizumab 1brodalumab 1Whole Genome Sequencing 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radionuclide Imaging 1Pluvicto 1Platinum 1Paclitaxel 1Laparoscopy 1Immunotherapy, Adoptive 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Liver Neoplasms × Ipilimumab × 90 days × Clear all
NCT07227012 2026-06-04

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Pfizer

Phase 1/2 Recruiting
138 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡